CRISPR IND Updates: E. coli, Beta Thalassemia, and...
Jan. 12, 2022
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Poseida Therapeutics
Main focus: CAR-T cell therapies and liver-directed gene-editing therapies
Company stage: Clinical
Diseases: B-cell, multiple myeloma and solid cancers
Genome editing technology: Cas-CLOVER
Funding stage: Public (NASDAQ:PSTX)
Location: San Diego, CA, USA
Website: https://poseida.com/
Pipeline: https://poseida.com/science/pipeline/
Partnerships: Takeda Pharmaceuticals
Poseida Therapeutics is a clinical-stage CAR-T and gene editing company. The company is focused on treating various cancer types such as multiple myeloma, prostate cancer and B-cell malignancies. Poseida uses a proprietary gene-editing technology known as Cas-CLOVER in order to induce multiple edits in the genomes of its CAR-T cell products.
